These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12144941)

  • 1. Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery.
    Broglio F; Guarracino F; Benso A; Gottero C; Prodam F; Granata R; Avogadri E; Muccioli G; Deghenghi R; Ghigo E
    Eur J Pharmacol; 2002 Jul; 448(2-3):193-200. PubMed ID: 12144941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity.
    Massoud AF; Hindmarsh PC; Matthews DR; Brook CG
    Clin Endocrinol (Oxf); 1996 May; 44(5):555-62. PubMed ID: 8762732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of GH/IGF-I axis in patients with dilated cardiomyopathy.
    Broglio F; Fubini A; Morello M; Arvat E; Aimaretti G; Gianotti L; Boghen MF; Deghenghi R; Mangiardi L; Ghigo E
    Clin Endocrinol (Oxf); 1999 Apr; 50(4):417-30. PubMed ID: 10468900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy.
    Imazio M; Bobbio M; Broglio F; Benso A; Podio V; Valetto MR; Bisi G; Ghigo E; Trevi GP
    Eur J Heart Fail; 2002 Mar; 4(2):185-91. PubMed ID: 11959048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.
    Arvat E; Maccario M; Di Vito L; Broglio F; Benso A; Gottero C; Papotti M; Muccioli G; Dieguez C; Casanueva FF; Deghenghi R; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1169-74. PubMed ID: 11238504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans.
    Bisi G; Podio V; Valetto MR; Broglio F; Bertuccio G; Del Rio G; Arvat E; Boghen MF; Deghenghi R; Muccioli G; Ong H; Ghigo E
    J Endocrinol Invest; 1999 Apr; 22(4):266-72. PubMed ID: 10342360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
    Ghigo E; Gianotti L; Arvat E; Ramunni J; Valetto MR; Broglio F; Rolla M; Cavagnini F; Müller EE
    J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone-independent cardiotropic activities of growth hormone-releasing peptides in normal subjects, in patients with growth hormone deficiency, and in patients with idiopathic or ischemic dilated cardiomyopathy.
    Broglio F; Benso A; Valetto MR; Gottero C; Quaranta L; Podio V; Arvat E; Bobbio M; Bisi G; Ghigo E
    Endocrine; 2001 Feb; 14(1):105-8. PubMed ID: 11322491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of desensitization by hexarelin to subsequent GH releasing hormone-mediated GH secretion in patients with anorexia nervosa.
    Popovic V; Micic D; Djurovic M; Obradovic S; Casanueva FF; Dieguez C
    Clin Endocrinol (Oxf); 1997 May; 46(5):539-43. PubMed ID: 9231048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The negative GH auto-feedback in childhood: effects of rhGH and/or GHRH on the somatotroph response to GHRH or hexarelin, a peptidyl GH secretagogue, in children.
    Bellone J; Bellone S; Aimaretti G; Valetto MR; Baffoni C; Corneli G; Origlia C; Arvat E; Ghigo E
    J Endocrinol Invest; 2000 Mar; 23(3):158-62. PubMed ID: 10803472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac ischemia and impairment of vascular endothelium function in hearts from growth hormone-deficient rats: protection by hexarelin.
    De Gennaro Colonna V; Rossoni G; Bernareggi M; Müller EE; Berti F
    Eur J Pharmacol; 1997 Sep; 334(2-3):201-7. PubMed ID: 9369349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Six-week treatment with hexarelin in young dogs: evaluation of the GH responsiveness to acute hexarelin or GHRH administration, and of the orexigenic effect of hexarelin.
    Rigamonti AE; Cella SG; Marazzi N; Müller EE
    Eur J Endocrinol; 1999 Sep; 141(3):313-20. PubMed ID: 10474131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hexarelin induced growth hormone release is influenced by exogenous growth hormone.
    Massoud AF; Hindmarsh PC; Brook CG
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):617-21. PubMed ID: 8548947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects.
    Arvat E; Gianotti L; Grottoli S; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1440-3. PubMed ID: 7962341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine, metabolic and cardioprotective effects of hexarelin in obese Zucker rats.
    De Gennaro-Colonna V; Rossoni G; Cocchi D; Rigamonti AE; Berti F; Muller EE
    J Endocrinol; 2000 Sep; 166(3):529-36. PubMed ID: 10974647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac effects of hexarelin in hypopituitary adults.
    Bisi G; Podio V; Valetto MR; Broglio F; Bertuccio G; Aimaretti G; Pelosi E; Del Rio G; Muccioli G; Ong H; Boghen MF; Deghenghi R; Ghigo E
    Eur J Pharmacol; 1999 Sep; 381(1):31-8. PubMed ID: 10528131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GH responsiveness to repeated GHRH or hexarelin administration in normal adults.
    Sartorio A; Conti A; Ferrero S; Spada A; Faglia G
    J Endocrinol Invest; 1995 Oct; 18(9):718-22. PubMed ID: 8719303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.
    Ghigo E; Arvat E; Gianotti L; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F
    J Clin Endocrinol Metab; 1994 Mar; 78(3):693-8. PubMed ID: 8126144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hexarelin stimulation of growth hormone release and mRNA levels in an infant and adult rat model of impaired GHRH function.
    Torsello A; Luoni M; Grilli R; Guidi M; Wehrenberg WB; Deghenghi R; Müller EE; Locatelli V
    Neuroendocrinology; 1997 Feb; 65(2):91-7. PubMed ID: 9067986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of anesthetic induction agents in patients with coronary artery disease and left ventricular dysfunction.
    Singh R; Choudhury M; Kapoor PM; Kiran U
    Ann Card Anaesth; 2010; 13(3):217-23. PubMed ID: 20826962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.